Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Autor: Cristina Loriente, Inmaculada Pérez, Montserrat López Rubio, Ana Cristina Godoy, María del Carmen Losada Castillo, Carolina Cuellar-García, Eduardo Ríos, Lucrecia Yáñez, Maria Dolores Garcia Malo, Ana Lario, Pau Abrisqueta, Julio Delgado, Mª José Berruezo, Alicia Smucler Simonovich, Alicia Rodríguez, Rafael Ramos, Miguel Villanueva, José Mª Arguiñano Pérez, Daniel Acha, Margarita Fernández de la Mata, Isidro Jarque, Javier Loscertales, Jose Luis Bello, Santiago Osorio, Paloma Martin, Angel Ramirez Payer, Macarena Ortiz, Ernesto Pérez Persona, Rubén Fernández Álvarez, Aima Lancharro Anchel, Jose Angel Hernandez-Rivas, Miguel Fernández-Zarzoso, Ana Célia Carneiro Oliveira, Patricia Baltasar, Angeles Medina, Mª Jesús Vidal Manceñido, Alexia Suarez, Ricardo García Muñoz, María José Terol, Fernando De Marco

Publikováno v: Clinical lymphoma, myeloma & leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Dipòsit Digital de la UB
Universidad de Barcelona

Ibrutinib demonstrated robust efficacy, regardless of high-risk features, in previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). The IBRORS-CLL study supports the effectiveness and the manageable safety profile of single-a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c4f2a1bd607572095c4a75307637b0
https://pubmed.ncbi.nlm.nih.gov/34511320

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Autor: Jose M Arguiñano, Angeles Medina, Ana Lario, Santiago Osorio-Prendes, Javier Loscertales, Lucrecia Yáñez, Patricia Baltasar, Fernando De Marco, Julio Delgado, Margarita Fernández de la Mata, Macarena Ortiz Pareja, Miguel Ganuza Fernandez, Inmaculada Pérez, Alicia Rodríguez, Rafael Ramos, Ana Cristina Godoy, Ruben Fernandez, Alexia Suárez Cabrera, Jose Luis Bello, Jose Angel Hernandez-Rivas, Carmen Losada, Montserrat López Rubio, Aima Lancharro Anchel, María-Jesús Vidal, Eduardo Rios Herranz, Angel Ramirez Payer, Isidro Jarque, Ana Célia Carneiro Oliveira, Maria José Berruezo, Pau Abrisqueta Costa, Carolina Cuellar, Paloma Martin, María-Dolores García-Malo, Ernesto Pérez Persona, María José Terol, Cristina Loriente, Alicia Smucler Simonovich, Ricardo Francisco Garcia, Miguel Villanueva

Publikováno v: Blood. 136:32-33

Introduction. Ibrutinib is a first-in-class, oral, once-a-day Bruton's tyrosine kinase inhibitor that achieves high overall response rates and durable remissions in patients with chronic lymphocytic leukemia (CLL) including those with high-risk featu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d76bf26c288ba86c1684e5da66b1577d
https://doi.org/10.1182/blood-2020-136036

Azacytidine for the treatment of myelodysplastic syndromes in the elderly

Autor: Maria Diez Campelo, Ana Cristina Godoy Molias, Regina Garcia Delgado, Jesus Feliu Sanchez

Publikováno v: Advances in therapy. 28

The management of myelodysplastic syndromes (MDS) in elderly patients is a significant clinical problem. The therapeutic options range from observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacyti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc91512ee3c915695c64ed53c244460e
https://pubmed.ncbi.nlm.nih.gov/21431505

Intrathecal Liposomal Cytarabine (DepoCyte®) for Treatment of Leptomeningeal Involvement From Transformed (Richter's syndrome) and Non-Transformed B-Cell Chronic Lymphocytic Leukemia (B-CLL) in Spain: Report of 8 Cases

Autor: Ana Cristina Godoy, José A. Fernández, Rodrigo Martino, Concepción Poderos, Rosa Fernández, Maria del Carmen Mateos, Ignacio De La Fuente, Jose Manuel Calvo-Villas

Publikováno v: Blood. 114:4411-4411

Abstract 4411 Background Leptomeningeal disease (LD) is an uncommon and severe complication in the course of B-CLL and may occur particularly in the course of transformation into an aggressive lymphoma, so-called Richter's syndrome. Commonly, repeate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d021ce1ce7879eba8c19ab521487fb74
https://doi.org/10.1182/blood.v114.22.4411.4411

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.